Pediatric headache: A comprehensive review

Wander A, Meena AK, Choudhary PK, Peer S, Singh R. Pediatric Headache: A Comprehensive Review. Ann Child Neurol. 2024;32(4):207-218.

Abstract

Pediatric headache is a common condition that often results in frequent outpatient visits. There are two broad etiological groups of headaches—primary and secondary headaches—with the former being more prevalent. Migraine, a type of primary headache, shares similarities with those experienced by adults, albeit with some variations in diagnostic criteria. The secondary causes of headache should be differentiated from the primary headaches with proper clinical evaluation and focussed investigations. The management of migraine focusses on lifestyle modifications, behavioral therapy, and pharmacotherapy for acute episodes and long-term preventive therapy. There are many novel promising treatment modalities. This review article provides an overview of pediatric headache epidemiology, classification, and pathophysiology and then elaborates on management and prevention strategies.

From the article:

1. Etiology

Headaches in children can be categorized into primary, where pain is a result of the headache condition itself, and secondary, where pain serves as a symptom of an underlying condition. Migraine and tension-type headaches are the most frequently encountered types of primary headaches in children. Cluster headache, a type of primary headache in children, exhibits similar characteristics to headaches in adults but is rare among young children. Upper respiratory tract infections are the commonest cause of secondary headaches that prompt emergency visits. Meningitis, hydrocephalus, and intracranial tumours are common etiologies of life-threatening headache in children. Frequently, no diagnosis can be reached despite an extensive evaluation. In a study involving 48,575 children aged 5 to 17 years who had headache disorders, about 19% were identified with primary headaches, 1.1% were diagnosed with secondary headaches, and 79.7% did not receive a formal diagnosis.

2. Pathophysiology

The pathophysiology of headaches is intricate, with genetic and environmental factors playing crucial roles in the development of migraine, tension-type headache, and cluster headache. However, identifying the specific genes involved has proven to be a challenging task. Familial hemiplegic migraine, which is linked to mutations in the calcium voltage-gated channel subunit alpha1 A (CACNA1A), ATPase Na+/K+ transporting subunit alpha 2 (ATP1A2), and sodium voltage-gated channel alpha subunit 1 (SCN1A) genes, and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), which is associated with a notch receptor 3 (NOTCH3) gene mutation, stand out as the most extensively studied headache disorders with a genetic foundation.

The vascular theory of migraines, according to which migraine stems from blood vessel dilation and that the aura is a result of vasoconstriction, is now deemed invalid, as evidenced by magnetic resonance angiography studies. A typical migraine episode consists of four phases: the prodromal or premonitory phase, the aura phase, the headache phase, and the post-dromal phase. The premonitory phase is characterized by irritability, fatigue, difficulty in concentration, nausea, or pallor. Functional neuroimaging studies suggest involvement of the hypothalamus in the premonitory phase, as well as during the migraine attack phase. The migraine aura constitutes a reversible neurological phenomenon impacting approximately one-third of all migraine sufferers and occasionally overlapping with the headache phase. The underlying mechanism of this phase is thought to involve cortical spreading depolarization (CSD) across the cortex. CSD is marked by a brief excitation period, followed by a prolonged depression of cortical activity. Originating from the occipital lobes, it propagates anteriorly, dissipates at the central sulcus, and influences neurotransmitter levels, ionic balance, and blood flow. The headache phase is characterized by the activation of the trigeminocervical complex. Neuropeptides, particularly calcitonin gene-related peptide (CGRP), are involved in trigeminal activation and have emerged as a potential target for therapeutic interventions in migraine patients. 

The development of cluster headaches involves interactions among the trigemino-vascular pathway, trigeminal autonomic reflex, hypothalamus, and the neuropeptides CGRP and pituitary adenylate cyclase-activating polypeptide. In tension-type headaches, the pain is thought to stem from myofascial structures and is heightened by central sensitization mechanisms. This central sensitization involves an imbalance in neurotransmitters such as CGRP, nitric oxide, neurokinin-A, glutamate, substance-P, serotonin, and endogenous peptide systems...

Conclusion

Pediatric headache is a prevalent condition in children, leading to substantial morbidity and frequent healthcare visits. The primary culprits are often primary headaches and acute viral infections. The initial assessment is essential for identifying potential warning signs, excluding secondary or life-threatening causes of headaches, and minimizing unnecessary investigations. Migraine is the most significant and common type of headache in children and adolescents. Prompt acute management of migraines involves supportive care and analgesics, but there is a lack of clear evidence-based recommendations for preventive therapy in children, highlighting a need for further research in this area. Newer modalities including non-invasive neuro-simulation botulinum toxin and CGRP antagonists are promising and emerging therapies. 

Phenomenology and clinical relevance of minor neurological signs in child neurology

Magostini F, Paris G, Capuano A. Phenomenology and clinical relevance of minor neurological signs in child neurology and psychiatry. Front Neurol. 2026 May 8;17:1761780. doi: 10.3389/fneur.2026.1761780. PMID: 42180220; PMCID: PMC13193831.

Abstract

Minor Neurological Signs, also referred to as neurological soft signs, are subtle abnormalities detected during neurological examination that do not meet criteria for major focal deficits. They are increasingly considered indicators of variability in neurodevelopment, likely reflecting differences in sensorimotor integration and maturation of cortico–subcortical networks. This mini review summarizes current evidence on the phenomenology, neurobiological correlates, and clinical relevance of MNS in child neurology and psychiatry. MNS include motor features such as overflow movements, dysmetria, dysrhythmia, and mild alterations in coordination, tone, and balance. Their assessment relies on standardized, developmentally appropriate tools that support identification of distinct patterns of dysfunction. MNS are frequently reported in neurodevelopmental and psychiatric conditions. While not diagnostically specific, they have been associated with symptom severity and functional outcomes. Further longitudinal and integrative studies are needed to clarify their developmental trajectories, neurobiological mechanisms, and potential clinical utility.

From the article:

In line with the movement disorders classification and subsequent classification efforts in the field of minor neurological signs, we can identify the following phenomenological categories:

1) Hyperkinetic movement disorders: these are characterized by involuntary movements, primarily manifesting as tremors, choreiform movements, and dystonic postures.

a) Tremor: defined as a rhythmic, oscillatory movement of a body part, resulting from alternating or synchronous contractions of antagonist muscles, and may occur at rest, during posture, or during action.

b) Choreiform movements: frequently described as “dance-like” or “piano playing movements”, consist of brief, irregular, non-rhythmic, and unpredictable movements that flow randomly from one body part to another, predominantly affecting the distal extremities. These movements are not suppressible and are characterized by variability in timing, amplitude, and distribution.

c) Dystonia: characterized by sustained or intermittent muscle contractions causing abnormal, often repetitive movements or postures. These movements are typically patterned, twisting, and may be triggered or worsened by voluntary action.

2) Overflow movements: these refer to involuntary movements of body parts that are not necessary to perform a motor task effectively. Notable examples include contralateral motor overflow and mirror movements.

3) Dysmetria: this is identified as an inability to control the trajectory of purposeful movements, particularly concerning coordination of the extremities.

4) Miscellaneous disturbances: this category includes mild alterations in muscle tone, abnormalities in balance and gait (e.g., tandem gait), lateralization and dysrhythmia (an impairment of motor timing and of the ability to generate, maintain, or synchronize temporal sequences of movement, resulting in irregularity in rhythmic execution and coordination).

Although individually non-specific, these signs reflect variations in the organization and integration of distributed sensorimotor networks and are commonly observed within the spectrum of minor neurological signs...

The systematic observation of MNS provides clinically relevant information on the functional organization of developing neural systems involved in motor control and sensory integration. Rather than directly informing etiology, MNS can be understood as observable markers of variability in the organization and functioning of subcortical and cortico–subcortical systems. However, their clinical relevance is often underestimated and not always fully recognized during assessment, despite their potential to support early identification of risk in children who do not yet meet full diagnostic criteria but present emerging signs of neurodevelopmental vulnerability.

In the clinical context, MNS should be conceptualized as structured, domain-specific configurations of signs that support the identification of neurodevelopmental subgroups. MNS can be interpreted as intermediate phenotypes along a spectrum that includes, on one end, transient maturational variations and, on the other, conditions characterized by structural and persistent deficits, such as cerebral palsy.

The systematic assessment of MNS using standardized and specific tools is essential to clinical practice. Recognizing MNS as central components of neurodevelopmental assessment may improve early diagnosis, refine phenotypic stratification, and support the implementation of earlier and more tailored interventions in neurodevelopmental disorders.

Multiple genetic etiologies causing Dandy-Walker variant with microcephaly, epilepsy, and global developmental delay.

Zhang LB, Wu YY, Qiu DJ, Li WB, Ye ZL. Child Neurology: Multiple Genetic Etiologies Causing Dandy-Walker Variant With Microcephaly, Epilepsy, and Global Developmental Delay. Neurology. 2026 Apr 14;106(7):e214793. doi: 10.1212/WNL.0000000000214793. Epub 2026 Mar 6. PMID: 41791021.

Abstract

Dandy-Walker syndrome is typically characterized by near-complete cerebellar vermis agenesis, enlarged posterior fossa, and dilated fourth ventricle. By contrast, Dandy-Walker variant (DWv) shows milder features, typically characterized by partial agenesis of the cerebellar vermis, mild enlargement of the posterior fossa, and variable dilation of the fourth ventricle. Both conditions are usually associated with normal or enlarged head circumference. We report a 16-month-old girl presenting with congenital microcephaly, frequent seizures, and severe global developmental delay. Brain MRI revealed findings consistent with DWv, which did not explain the severity of her clinical symptoms or her microcephaly. Chromosomal microarray analysis revealed multiple regions of homozygosity on chromosome 11, indicating potential recessive inheritance; karyotype analysis and mitochondrial testing showed no clear etiology. Trio-based whole-exome sequencing identified a heterozygous variant (NM_021096.4:c.4891T>A/p.Phe1631Ile) in CACNA1I and a homozygous variant (NM_002335.4:c.1310C>T/p.Thr437Met) in LRP5. Variants in CACNA1I are associated with neurodevelopmental disorders, including epilepsy and developmental delay, while variants in LRP5 are linked to osteoporosis and microcephaly. Based on the clinical presentation and molecular findings, we hypothesize that both variants contributed to the patient's complex phenotype. This case highlights that in patients with unusually severe or atypical manifestations, the possibility of multiple genetic pathogenic contributions should be considered, and comprehensive genomic evaluation is essential for accurate diagnosis and management.

Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient

Cellucci T, Van Mater H, Graus F, Muscal E, Gallentine W, Klein-Gitelman MS, Benseler SM, Frankovich J, Gorman MP, Van Haren K, Dalmau J, Dale RC. Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient. Neurol Neuroimmunol Neuroinflamm. 2020 Jan 17;7(2):e663. doi: 10.1212/NXI.0000000000000663. Erratum in: Neurol Neuroimmunol Neuroinflamm. 2020 Apr 15;7(4):e730. doi: 10.1212/NXI.0000000000000730. PMID: 31953309; PMCID: PMC7051207.

Abstract

Objective: Autoimmune encephalitis (AE) is an important and treatable cause of acute encephalitis. Diagnosis of AE in a developing child is challenging because of overlap in clinical presentations with other diseases and complexity of normal behavior changes. Existing diagnostic criteria for adult AE require modification to be applied to children, who differ from adults in their clinical presentations, paraclinical findings, autoantibody profiles, treatment response, and long-term outcomes.

Methods: A subcommittee of the Autoimmune Encephalitis International Working Group collaborated through conference calls and email correspondence to consider the pediatric-specific approach to AE. The subcommittee reviewed the literature of relevant AE studies and sought additional input from other expert clinicians and researchers.

Results: Existing consensus criteria for adult AE were refined for use in children. Provisional pediatric AE classification criteria and an algorithm to facilitate early diagnosis are proposed. There is also discussion about how to distinguish pediatric AE from conditions within the differential diagnosis.

Conclusions: Diagnosing AE is based on the combination of a clinical history consistent with pediatric AE and supportive diagnostic testing, which includes but is not dependent on antibody testing. The proposed criteria and algorithm require validation in prospective pediatric cohorts.

Last American to use an iron lung dies

A 78-year-old Oklahoma woman who was diagnosed with polio as a child and was the last American to rely on an iron lung to live has died.

Martha Lillard found out she had the once-feared disease when she was 5 years old, which left her paralyzed from the neck down, and required her to use the machine to help her breathe while she slept.

Lillard contracted COVID-19 twice during the pandemic, which left her in the machine nearly 24 hours a day.

"They told her she wasn't supposed to live past 20 years old," her younger sister, Cindy McVey, told The Associated Press on Friday. "She had the enthusiasm and the drive to continue living and make the best of her life."

Despite having polio, Lillard was able to go to school two hours a day as a child, and she had tutors the rest of the time. She also used an intercom phone system that allowed her to interact with her teachers and classmates from home.

Lillard was even able to take road trips as a child because of a custom trailer that could accommodate the iron lung and her father making sure their hotels had wide enough doors for the machine.

An iron lung is a negative-pressure ventilator that helps a patient with paralyzed lung muscles breathe.

The disease once caused thousands of cases of paralysis in children during outbreaks each year in the first part of the 20th century before a vaccine became available in 1955.

By 1979, polio was considered eliminated in the U.S.

Later, Lillard was able to regain the use of her left arm and legs through therapy and was even able to drive for a time.

She lived independently for many years, even getting married earlier this year to a man from Egypt she corresponded with for two decades after he was able to obtain a visa.

"They were really soul mates," McVey said. "He's extremely brokenhearted."

Lillard, who wrote poetry and volunteered with the Humane Society, according to her sister, had just 25% lung capacity before she was diagnosed with COVID.

https://www.foxnews.com/health/last-american-use-iron-lung-dies-78-years-old-childhood-polio-diagnosis

Riboflavin transporter deficiency and energy dysmetabolism

Colasuonno F, Marioli C, Tartaglia M, Bertini E, Compagnucci C, Moreno S. New Insights into the Neurodegeneration Mechanisms Underlying Riboflavin Transporter Deficiency (RTD): Involvement of Energy Dysmetabolism and Cytoskeletal Derangement. Biomedicines. 2022 Jun 6;10(6):1329. doi: 10.3390/biomedicines10061329. PMID: 35740351; PMCID: PMC9219947.

Abstract

Riboflavin transporter deficiency (RTD) is a rare genetic disorder characterized by motor, sensory and cranial neuropathy. This childhood-onset neurodegenerative disease is caused by biallelic pathogenic variants in either SLC52A2 or SLC52A3 genes, resulting in insufficient supply of riboflavin (vitamin B2) and consequent impairment of flavoprotein-dependent metabolic pathways. Current therapy, empirically based high-dose riboflavin supplementation, ameliorates the progression of the disease, even though response to treatment is variable and partial. Recent studies have highlighted concurrent pathogenic contribution of cellular energy dysmetabolism and cytoskeletal derangement. In this context, patient specific RTD models, based on induced pluripotent stem cell (iPSC) technology, have provided evidence of redox imbalance, involving mitochondrial and peroxisomal dysfunction. Such oxidative stress condition likely causes cytoskeletal perturbation, associated with impaired differentiation of RTD motor neurons. In this review, we discuss the most recent findings obtained using different RTD models. Relevantly, the integration of data from innovative iPSC-derived in vitro models and invertebrate in vivo models may provide essential information on RTD pathophysiology. Such novel insights are expected to suggest custom therapeutic strategies, especially for those patients unresponsive to high-dose riboflavin treatments.

Marioli C, Magliocca V, Petrini S, Niceforo A, Borghi R, Petrillo S, La Rosa P, Colasuonno F, Persichini T, Piemonte F, Massey K, Tartaglia M, Moreno S, Bertini E, Compagnucci C. Antioxidant Amelioration of Riboflavin Transporter Deficiency in Motoneurons Derived from Patient-Specific Induced Pluripotent Stem Cells. Int J Mol Sci. 2020 Oct 7;21(19):7402. doi: 10.3390/ijms21197402. PMID: 33036493; PMCID: PMC7582490.

Abstract

Mitochondrial dysfunction is a key element in the pathogenesis of neurodegenerative disorders, such as riboflavin transporter deficiency (RTD). This is a rare, childhood-onset disease characterized by motoneuron degeneration and caused by mutations in SLC52A2 and SLC52A3, encoding riboflavin (RF) transporters (RFVT2 and RFVT3, respectively), resulting in muscle weakness, ponto-bulbar paralysis and sensorineural deafness. Based on previous findings, which document the contribution of oxidative stress in RTD pathogenesis, we tested possible beneficial effects of several antioxidants (Vitamin C, Idebenone, Coenzyme Q10 and EPI-743, either alone or in combination with RF) on the morphology and function of neurons derived from induced pluripotent stem cells (iPSCs) from two RTD patients. To identify possible improvement of the neuronal morphotype, neurite length was measured by confocal microscopy after β-III tubulin immunofluorescent staining. Neuronal function was evaluated by determining superoxide anion generation by MitoSOX assay and intracellular calcium (Ca2+) levels, using the Fluo-4 probe. Among the antioxidants tested, EPI-743 restored the redox status, improved neurite length and ameliorated intracellular calcium influx into RTD motoneurons. In conclusion, we suggest that antioxidant supplementation may have a role in RTD treatment.

Colasuonno F, Niceforo A, Marioli C, Fracassi A, Stregapede F, Massey K, Tartaglia M, Bertini E, Compagnucci C, Moreno S. Mitochondrial and Peroxisomal Alterations Contribute to Energy Dysmetabolism in Riboflavin Transporter Deficiency. Oxid Med Cell Longev. 2020 Aug 12;2020:6821247. doi: 10.1155/2020/6821247. PMID: 32855765; PMCID: PMC7443020.

Abstract

Riboflavin transporter deficiency (RTD) is a childhood-onset neurodegenerative disorder characterized by progressive pontobulbar palsy, sensory and motor neuron degeneration, sensorineural hearing loss, and optic atrophy. As riboflavin (RF) is the precursor of FAD and FMN, we hypothesize that both mitochondrial and peroxisomal energy metabolism pathways involving flavoproteins could be directly affected in RTD, thus impacting cellular redox status. In the present work, we used induced pluripotent stem cells (iPSCs) from RTD patients to investigate morphofunctional features, focusing on mitochondrial and peroxisomal compartments. Using this model, we document the following RTD-associated alterations: (i) abnormal colony-forming ability and loss of cell-cell contacts, revealed by light, electron, and confocal microscopy, using tight junction marker ZO-1; (ii) mitochondrial ultrastructural abnormalities, involving shape, number, and intracellular distribution of the organelles, as assessed by focused ion beam/scanning electron microscopy (FIB/SEM); (iii) redox imbalance, with high levels of superoxide anion, as assessed by MitoSOX assay accompanied by abnormal mitochondrial polarization state, evaluated by JC-1 staining; (iv) altered immunofluorescence expression of antioxidant systems, namely, glutathione, superoxide dismutase 1 and 2, and catalase, as assessed by quantitatively evaluated confocal microscopy; and (v) peroxisomal downregulation, as demonstrated by levels and distribution of fatty acyl β-oxidation enzymes. RF supplementation results in amelioration of cell phenotype and rescue of redox status, which was associated to improved ultrastructural features of mitochondria, thus strongly supporting patient treatment with RF, to restore mitochondrial- and peroxisomal-related aspects of energy dysmetabolism and oxidative stress in RTD syndrome.

Shades of Questcor 8

I hold my nose and prescribe.

How much money does the manufacturer of Valtoco make?

The manufacturer of Valtoco, Neurelis, Inc., generated an estimated $295 million to $300 million in net sales for the full year of 2025. Because Valtoco is their flagship commercial product, it drives the vast majority of this revenue.

A breakdown of Neurelis' financial performance highlights their latest earnings structure:

Net Sales Growth: The $295–$300 million figure for 2025 represents an immense jump, more than doubling their 2024 net sales figures.

Profitability: The company reported an EBITDA margin of 30%+, meaning their core operating profitability is roughly $90 million or more before accounting for interest, taxes, depreciation, and amortization.Cash Reserves: As of December 31, 2025, Neurelis held $175+ million in cash with zero bank debt.

Growth Catalysts: Sales spiked dramatically following the FDA indication expansion allowing children ages 2 to 5 to be prescribed the nasal spray.

Google AI

______________________________________________________

Why is Valtoco so expensive?

AI Overview

Valtoco is expensive because it is a brand-name medication with no generic alternative. Its high cost reflects the years of research and clinical trials required to develop its specialized, needle-free nasal delivery system, alongside the proprietary Intravail absorption technology. 

Because it is a patented pharmaceutical manufactured by Neurelis, there are no competitors to drive down the retail price, which can easily exceed $380 to $1,000+ depending on the prescribed dosage. However, according to discussion on the r/Epilepsy Reddit Forum, users agree that the prohibitive retail prices can be bypassed using manufacturer savings programs and patient assistance programs, often bringing costs down significantly. 

Patients prescribed Valtoco can utilize several tools to reduce their out-of-pocket costs: 

Manufacturer Co-Pay Cards: Patients with commercial insurance can often pay as little as $20 through the VALTOCO Co-Pay Card Program.

Patient Assistance Programs: Uninsured or underinsured patients may qualify to receive the medication at no cost through the myNEURELIS Support Program.

Discount Cards: Using tools like the GoodRx Valtoco Page can also provide pharmacy coupons that drop the cash price well below retail. 

Google AI

____________________________________________________________

https://www.goodrx.com/compare/valtoco-vs-nayzilam?srsltid=AfmBOoqX1pJPJOst4uJ4rSnKKPZYn5bM43xB8ft4cw03pqGiX3lfJmio